Sustained-Release Microspheres of Rivoceranib for the Treatment of Subfoveal Choroidal Neovascularization
The wet type of age-related macular degeneration (AMD) accompanies the subfoveal choroidal neovascularization (CNV) caused by the abnormal extension or remodeling of blood vessels to the macula and retinal pigment epithelium (RPE). Vascular endothelial growth factor (VEGF) is known to play a crucial...
Main Authors: | E Seul Kim, Min Sang Lee, Hayoung Jeong, Su Yeon Lim, Doha Kim, Dahwun Kim, Jaeback Jung, Siyan Lyu, Hee Joo Cho, Dong Min Kim, Wonhee Suh, Ji Hoon Jeong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/10/1548 |
Similar Items
-
Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization
by: Hyeon Jeong Yoon, et al.
Published: (2019-11-01) -
Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization
by: Hussain Nazimul, et al.
Published: (2006-01-01) -
Changes of subfoveal choroidal thickness after treated by Ranibizumab for choroidal neovascularization secondary to pathologic myopia
by: Jian-Shu Yuan, et al.
Published: (2016-05-01) -
Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks
by: Sachdev Nishant, et al.
Published: (2007-01-01) -
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE)
by: Matthew Gumbleton, et al.
Published: (2023-02-01)